Villin 1 is a predictive factor for the recurrence of high serum alpha-fetoprotein-associated hepatocellular carcinoma after hepatectomy

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1493-1501

  Xieraili, Maimaiti ^a   Yasen, Mahmut ^a,b   Mogushi, Kaoru ^a   Obulhasim, Gulanbar ^a,b   Mayinuer, Abudureheman ^a   Aihara, Arihiro ^a   Tanaka, Shinji ^a   Mizushima, Hiroshi ^a   Tanaka, Hiroshi ^a   Arii, Shigeki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; VILLIN; VILLIN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UPREGULATION;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MICROFILAMENT PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864308744     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02315.x     Document Type: Article

References (35)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-87.
2. But DYK, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1652-6.
3. Arii S, Yamaoka Y, Futagawa S et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group Japan. Hepatol 2000; 32: 1224-9.
4. Tanaka S, Noguchi N, Ochiai T et al. Outcomes and recurrence of initially resection of hepatocellular carcinoma meeting Milan Criteria: raionale for partial hepatectomy as first strategy. J Am Coll Surg 2007; 204: 1-6.
5. Iizuka N, Oka M, Yamada-Okabe H et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361: 923-9.
6. Ho MC, Lin JJ, Chen CN et al. A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. Ann Surg Oncol 2006; 13: 1474-84.
7. Tanaka S, Arii S, Yasen M et al. Aurora kinase B is a predictive factor for aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 2008; 95: 611-9.
8. Tanaka S, Mogushi K, Yasen M et al. Surgical contribution to recurrence-free survival in patients with macrovascular-invasion-negative hepatocellular carcinoma. J Am Coll Surg 2009; 208: 368-74.
9. Arrigoni A, Andriulli A, Gindro T, Piantino P, Capussotti L, Rizzetto M. Pattern analysis of serum alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma in liver cirrhosis. Int J Biol Markers 1988; 3: 172-6.
10. Tangkijvanich P, Anukulkarnkusol N, Suwangool P et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-8.
11. Morimoto O, Nagano H, Miyamoto A et al. Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood. Surg Today 2005; 35: 1033-41.
12. Kamiyama T, Takahashi M, Nakagawa T et al. AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg 2006; 244: 451-63.
13. Okuda N, Nakao A, Takeda S et al. Clinical significance of alpha-fetoprotein mRNA during perioperative period in HCC. Hepatogastroenterology 1999; 46: 381-6.
14. Jeng KS, Sheen IS, Tsai YC. Circulating messenger RNA of alpha-fetoprotein: a possible risk factor of recurrence after resection of hepatocellular carcinoma. Arch Surg 2004; 139: 1055-60.
15. Tomasi TB Jr. Structure and function of alpha-fetoprotein. Annu Rev Med 1977; 28: 453-65.
16. Wang XW, Xie H. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci 1999; 64: 17-23.
17. Dudich E, Semenkova L, Gorbatova E et al. Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumour Biol 1998; 19: 30-40.
18. Semenkova LN, Dudich EI, Dudich IV. Induction of apoptosis in human hepatoma cells by alpha-fetoprotein. Tumour Biol 1997; 18: 261-73.
19. Dudich E, Semenkova L, Dudich I et al. Alpha-fetoprotein causes apoptosis in tumor cells via a pathway independent of CD95, TNFR1 and TNFR2 through activation of caspase-3-like proteases. Eur J Biochem 1999; 266: 750-61.
20. Yasen M, Mizushima H, Mogushi K et al. Expression of Aurora B and alternative forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci 2009; 100: 472-80.
21. Shigeru S, Hidenori O, Hitoshi I, Setsuo H, Tadashi K. Molecular background of a-fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Sci 2008; 99: 2402-9.
22. Bretscher A, Weber K. Villin is a major protein of the microvillus cytoskeleton which binds both G and F actin in a calcium-dependent manner. Cell 1980; 20: 839-47.
23. Nambu Y, Iannettoni MD, Orringer MB, Beer DG. Unique expression patterns and alterations in the intestinal protein villin in primary and metastatic pulmonary adenocarcinomas. Mol Carcinog 1998; 23: 234-42.
24. Khurana P, Henty JL, Huang S, Staiger AM, Blanchoin L, Staiger CJ. Arabidopsis VILLIN1 and VILLIN3 have overlapping and distinct activities in actin bundle formation and turnover. Plant Cell 2010; 22: 2727-48.
25. Moll R, Robine S, Dudouet B, Louvard D. Villin: a cytoskeletal protein and a differentiation marker expressed in some human adenocarcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1987; 54: 155-69.
26. Bacchi CE, Gown AM. Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: a study employing paraffin-embedded tissue. Lab Invest 1991; 64: 418-24.
27. Wang Y, Srinivasan K, Siddiqui MR, George SP, Tomar A, Khurana S. A novel role for villin in intestinal epithelial cell survival and homeostasis. J Biol Chem 2008; 283: 9454-64.
28. Khurana S, George SP. Regulation of cell structure and function by actin-binding proteins: Villin's perspective. FEBS Lett 2008; 582: 2128-39.
29. Zhang PJ, Harris KR, Alobeid B, Brooks JJ. Immunoexpression of villin in neuroendocrine tumors and its diagnostic implications. Arch Pathol Lab Med 1999; 123: 812-6.
30. Rimm DL, Holland TE, Morrow JS, Anderson JM. Autoantibodies specific for villin found in patients with colon cancer and other colitides. Dig Dis Sci 1995; 40: 389-95.
31. Xi L, Gooding W, McCarty K, Godfrey TE, Hughes SJ. Identification of mRNA markers for molecular staging of lymph nodes in colorectal cancer. Clin Chem 2006; 52: 520-3.
32. Nagashio R, Sato Y, Jiang SX et al. Detection of tumor-specific autoantibodies in sera of patients with lung cancer. Lung Cancer 2008; 62: 364-73.
33. Nakamura E, Iwakawa M, Furuta R et al. Villin1, a novel diagnostic marker for cervical adenocarcinoma. Cancer Biol Ther 2009; 8: 1146-53.
34. Nakamura E, Satoh T, Iwakawa M et al. Villin1, a diagnostic marker for endometrial adenocarcinoma with high grade nuclear atypia. Cancer Biol Ther 2011; 12: 181-90.
35. Murakata A, Tanaka S, Mogushi K et al. Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg 2011; 253: 94-100.